The PEMED 2018 conference will gather 12 high-profile Personalized and Precision Medicine experts to deliver plenary speeches.
Prof. Anne-Marie Caminade
Coordination Chemistry Lab of Toulouse and University of Toulouse, France
Anne-Marie Caminade is Director of Research Exceptional Class at the CNRS, and the head of the “Dendrimers and Heterochemistry” group at the LCC-Toulouse (France). After two PhDs in Toulouse and two Post-docs (IFP-Paris and Von Humboldt fellow in Saarbrücken), she holds a CNRS researcher position since 1985. She developed several aspects of phosphorus chemistry. Her current research interest is on dendrimers (hyperbranched nanomolecules), in particular on their use as catalysts, for nanomaterials and for biology/nanomedicine. She is the co-author of about 445 publications, 50 book chapters, 2 books, and 30 patents (h index 61).
Talk title: How can dendrimers contribute to precision/personalized medicine?
Prof. Klaus Pantel
Center for Experimental Medicine – Institute of Tumor Biology, Germany
Prof Pantel is Chairman of the Institute of Tumour Biology at the University Medical Center Hamburg-Eppendorf. The institute is part of the Centre of Experimental Medicine and the University Cancer Center Hamburg (UCCH). The pioneer work of Prof Pantel in the field of cancer micrometastasis, circulating tumor cells and circulating nucleic acids (ctDNA, microRNAs) is reflected by more than 400 publications in excellent high ranking biomedical and scientific journals (incl. NEJM, Lancet, Nature Journals, Cancer Cell, Science Translational Medicine, Cancer Discovery, PNAS, JCO, JNCI, Cancer Res.) and has been awarded the AACR Outstanding Investigator Award 2010, German Cancer Award 2010, and ERC Advanced Investigator Grant 2011. Moreover, Prof Pantel coordinates the European TRANSCAN group “CTC-SCAN”, the European IMI consortium CANCER-ID (www.cancer-id.eu) on blood-based “Liquid Biopsies” and serves on the Editorial Boards of international cancer journals (e.g., Breast Cancer Res., Cancer Res.).
Talk title: coming soon
Prof. Jacques Beckmann
University of Lausanne, Switzerland
Jacques S. Beckmann was, from 2013 till 2016, head of clinical bioinformatics at the SIB Swiss Institute of Bioinformatics. From 2003-2012, he was Professor of Human Genetics and Director of the Dept. of Medical Genetics at the Univ. of Lausanne (UNIL) and of the Medical Genetics Service of the Centre Hospitalier Universitaire Vaudois (CHUV). Previously, he held a chair as Full Professor at the Dept. of Molecular Genetics at the Weizmann Institute of Science, Rehovot, Israel. Initially trained in molecular genetics he then moved to genetics, and pioneered in the 1980s the use of marker-assisted genetic improvement in plants and animals, focusing on Quantitative Trait Loci (QTLs). His interest shifted in 1990 to human genetics with a move to Paris, where he held successively senior research positions at the CEPH, Généthon (Evry), and finally, was involved, together with Mark Lathrop, in the creation of the Centre National de Génotypage (CNG, Evry), where he served as Deputy-Director. During those years, he contributed significantly to the elaboration of genetic, physical and gene maps of the human genome, as well as to the positional cloning of a number of disease loci involved in muscular dystrophy, diabetes and other diseases. His recent research interests also included genomic disorders as well as the genetic basis of complex traits. Prof. Beckmann has published 400 scientific peer-reviewed articles in molecular genetics, genetics and genomics and with about 36’000 citations has an ISI H-index of 96 (www.researcherid.com/rid/A-9772-2008). He served on the editorial boards of several scientific journals and is or has been a board member of the ESHG, ENMC, Italian Telethon, HGVS committees, INRA, E-Rare, La Fondation des Maladies Rares and the Jérôme Lejeune Foundation as well as a member of the Scientific Advisory Board of the French GenMed and of the France Génomique programs. In Switzerland, he took part in several committees that contributed to establish the national program towards personalized health.
Talk title: coming soon
Prof. Anna Dominiczak
University of Glasgow, UK
Professor Dame Anna Dominiczak is Regius Professor of Medicine, Vice Principal and Head of College of Medical, Veterinary and Life Sciences at the University of Glasgow as well as honorary consultant physician and non-executive member of NHS Greater Glasgow and Clyde Health Board. In 2016, she was awarded a DBE for services to cardiovascular and medical science.
Professor Dominiczak is one of the world’s leading cardiovascular scientists and clinical academics. She held a British Heart Foundation Chair of Cardiovascular Medicine at the University of Glasgow between 1997 and 2010, and directorship of the Cardiovascular Research Centre between 2000 and 2010. Her major research interests are in hypertension, cardiovascular genomics and precision medicine, where she has not only published extensively in top peer-reviewed journals (almost 400 publications), but also excelled in large scale research funding for programmes and infrastructure (with a total value of over £70M in the last five years). She has also led a collaboration of four universities, four academic NHS Health Boards across Scotland and two major industrial partners to develop a public/private partnership in Precision Medicine with a current value in excess of £20M.
Professor Dominiczak is a Fellow of the Royal College of Physicians, the Academy of Medical Sciences, the Royal Society of Edinburgh, the American Heart Association and the European Society of Cardiology as well as a member of the Association of Physicians of Great Britain and Ireland, the British Cardiovascular Society, the British Hypertension Society, the European Society of Hypertension and the International Society of Hypertension. She was President of the European Society of Hypertension from 2013 to 2015. Since 2012, she has been Editor-in-Chief of Hypertension, journal of the American Heart Association and the world’s top journal in her area of research.
Talk title: From cardiovascular genomics to interdisciplinary precision medicine
Prof. Yosef Yarden
Weizmann Institute of Science, Israel
Born in Israel, Prof. Yosef Yarden received his BSc in biological and geological sciences from the Hebrew University of Jerusalem (1980), and a PhD in molecular biology from the Weizmann Institute of Science (1985). His postdoctoral training was undertaken at Genentech, Inc., in San Francisco and at the Massachusetts Institute of Technology. In 1988, he joined the Weizmann Institute of Science’s faculty. At the Institute, he has served as Dean of the Faculty of Biology (1997-1999), Vice President for Academic Affairs (1999-2001), the first Director of the MD Moross Institute for Cancer Research (1999-2001), and Dean of the Feinberg Graduate School (2001-2007). He is the new director of the Dwek Institute for Cancer Therapy Research of the Moross Integrated Cancer Center and became the head of the Department of Biological Regulation in June, 2017. He is the Harold and Zelda Goldenberg Professor of Molecular Cell Biology.
Prof. Yarden’s research focuses on a vital family of proteins called “growth factors,” hormone-like molecules that play a critical role in embryo development and in wound healing; and, particularly, on a group of four membrane-bound cellular proteins known as “epidermal growth factor receptors.” His research is helping to shed light on the way growth factors and their receptors promote tumor growth. Prof. Yarden discovered the function of a molecular amplifier, called HER2, that strengthens the chemical signals that cause cells to become cancerous. This amplifier is an enzyme and a receptor found in large quantities on cancerous cell membranes, especially in breast, ovary, and gastric tumors. This finding established a foundation for new cancer treatments based on “silencing” the molecular amplifier.
From 2011 till 2014 Prof. Yarden served as President of the Federations of Israeli Societies of Experimental Biology (FISEB/ILANIT). Among his many honors and awards are the Israel Prize in Life Sciences (2017), the EMET Prize in Biochemistry (2007), the 43rd Leoplod Griffuel Award of Fondation ARC pour la Recherche sur le Cancer (2015), the Susan G. Komen for the Cure® Brinker Award for Scientific Distinction in Basic Research (2012), the Ernst W. Bertner Memorial Award of the University of Texas’ MD Anderson Cancer Center (2010), the 2008 Hamilton Fairly Award of the European Societies of Clinical Oncology (ESMO), the MERIT award of the U.S. National Cancer Institute (2005), the TEVA Founders Prize (2004), and the Michael Bruno Prize of the Yad Hanadiv (Rothschild) Fund (2000). He was elected to the Israel Academy of Science and Humanities in 2007.
Talk title: coming soon
Prof. Matthias Schwab
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, and Department of Clinical Pharmacology, University Hospital, Tuebingen, Germany
Since 2007 Prof. Matthias Schwab is chair of Clinical Pharmacology at the University Tuebingen and director of the Department of Clinical Pharmacology, University Hospital Tuebingen and the Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (IKP) at Robert-Bosch-Hospital in Stuttgart, Germany. After the study of medicine at the University Erlangen-Nuernberg, Germany followed by fellowships in Children’s Medicine and Clinical Pharmacology with board certifications for both disciplines he has held positions at the IKP, Stuttgart, Germany and as visiting professor at St Jude Children’s Research Hospital, Memphis, US. In 2006 and in 2010 he declined two offers for Full Professorship and Chair for Clinical Pharmacology in Innsbruck, Austria, and Stockholm, Sweden. Prof. Schwab’s scientific interests focus on personalized medicine and pharmacogenomics (e.g. cancer therapy) particularly related to ADME genes. In addition, his special interest lies in the consideration of the application of novel –omics technologies as well as the implementation of research findings into clinical practice. Throughout his career Matthias Schwab received numerous awards such as the Galenus von Pergamon Award, the Robert-Pfleger Research Award or the “Staufer-Medal” conferred by the Prime Minister of Baden-Württemberg. He is also Member of the German National Academy of Sciences Leopoldina as well as of the Academy of Sciences and Literature, Mainz, Germany. His scientific accomplishments result in > 300 peer reviewed publications as well as around 19.000 citations and an ISI H-index of 73. Prof. Schwab is listed as Thomson Reuters Highly Cited Researcher 2015, 2016/2017 in the rubric “Pharmacology and Toxicology” and serves as Editor-in-Chief of Pharmacogenetics & Genomics as well as Section Editor of Genome Medicine for Pharmacogenomics & Personalized Medicine.
Talk title: Pharmacogenomics and Epigenetics: Update and Future Directions
Prof. Richard Weinshilboum
Mayo Clinic, USA
Dr. Weinshilboum received B.A. and M.D. degrees from the University of Kansas, followed by residency training in Internal Medicine at the Massachusetts General Hospital in Boston. He was also a Pharmacology Research Associate at the NIH in the laboratory of Nobel Laureate Dr. Julius Axelrod. He is presently Professor of Pharmacology and Medicine and Dasburg Professor of Cancer Genomics Research at Mayo. He also co-directs the Pharmacogenomics Program of the Mayo Center for Individualized Medicine. Dr. Weinshilboum’s research has focused on pharmacogenomics, with over 420 manuscripts on that topic. His major area of research has been the pharmacogenetics of drug metabolism, with a focus on methylation and sulfation. He has also applied genome-wide “omics” to study drug response–especially the drug therapy of depression and breast cancer. Dr. Weinshilboum has been the recipient of many awards including an Established Investigatorship of the American Heart Association, a Burroughs Wellcome Scholar Award in Clinical Pharmacology, the Oscar B. Hunter Award of the American Society for Clinical Pharmacology and Therapeutics, the ASPET Harry Gold Award and the Edvard Poulsson Award from the Norwegian Pharmacology Society. He has also served on the Advisory Councils for two US NIH Institutes, the NIGMS and NHGRI.
Talk title: Pharmacogenomics to Pharmaco-omics: Precision Medicine and Drug Response
Prof. Xiangyang Shi
Donghua University, China
Prof. Xiangyang Shi graduated with B.Sc. (chemistry, Henan Normal University, Xinxiang), M.E. (applied chemistry, Beijing Institute of Technology, Beijing), and Ph.D. (organic chemistry, Institute of Photographic Chemistry, the Chinese Academy of Sciences, Beijing) in 1992, 1995 and 1998, respectively. He worked as a Postdoctoral Fellow in Tsinghua University (1998-2000, Beijing) and Max-Planck Institute of Colloids and Interfaces (2000-2001, Potsdam, Germany). He then moved to California State University, Los Angeles (2001-2002) as a visiting scholar. From 2002-2008, he worked as a Research Fellow, Research Associate II, Research Investigator, and Research Assistant Professor at the University of Michigan, Ann Arbor. He then became a professor of special appointment both in Donghua University and in Shanghai Institutions of High Learning (Eastern Scholar) since 2008. Since 2010 he is also appointed as an “Invited Chair in Nanotechnology” at University of Madeira, Portugal. Prof. Shi has authored or coauthored 275 SCI-indexed peer-reviewed journal articles with an H-index of 57 and 251 technical conference abstracts or proceeding papers, along with 12 invited book chapters and 68 approved patents. His publications have been cited for over 10291 times. His research expertise includes dendrimer chemistry and organic/inorganic hybrid nanomaterials for nanomedicinal applications, in particular cancer diagnosis and therapy.
Talk title: Preparation of functional nanogels for tumor imaging and therapy
Prof. Fabrice André
Gustave Roussy Institute, France
Fabrice André, MD, PhD, received his MD in Grenoble in 2002, and a PhD in Biotechnology from Paris University in 2005. He is a past recipient of Young Investigator and Career Development awards from the American Society of Clinical Oncology (ASCO). He is currently Professor in the Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France. Professor André is conducting research in the field of biomarkers and personalised therapies. His research work focuses on biomarker discovery, development of targeted agents and implementation of personalised medicine. His team includes 70 people working on basic sciences, bioinformatics, biotechnologies and clinical research. Professor André is also leading phase I-III trials testing targeted agents in the field of breast cancer and large national trials testing implementation of high throughput technologies in the health care system. He has published more than 200 peer reviewed papers, including papers in the New England Journal of Medicine, Lancet, Nature Medicine, Science, Lancet Oncology and Journal of Clinical Oncology, either as main or co-author. Professor André is chairman of the biomarker group at UNICANCER (French cooperative group). He was a member of several scientific committees for international meetings, including SABCS, AAACR, ECCO, ESMO, and IMPAKT.
Talk title: Coming soon
Dr. Philip Murphy
National Institute of Allergy and Infectious Diseases, USA
Philip M. Murphy is a Senior Investigator and Chief of the Laboratory of Molecular Immunology (LMI) at the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health in Bethesda. Dr. Murphy received his undergraduate degree from Princeton in 1975 and medical degree from Cornell in 1981, and trained in Internal Medicine at New York University-Bellevue Hospital Center where he was Chief Resident in 1984-85. Since then he has conducted biomedical research at NIAID. Dr. Murphy’s research has focused on leukocyte chemotactic receptors, from their basic molecular and biologic properties to their roles in human disease. His discoveries include 1) the first CXC and CC chemokine receptors, 2) the first neutrophil-, monocyte- and eosinophil-selective chemoattractant receptors, 3) the family of N-formylpeptide receptors, 4) the first virally-encoded chemokine receptors, 5) the HIV coreceptor CCR5 and the HIV genetic restriction factor CCR532, 6) the role of CCR5 in West Nile virus pathogenesis, and 7) the role of CX3CR1 in atherogenesis. More recently he has initiated a clinical program to develop mechanism-based therapy targeting the chemokine receptor CXCR4 in a rare immunodeficiency disorder known as WHIM syndrome, and has pioneered studies to define the role of chemoattractant receptors on non-hematopoietic cells and in behavior. Dr. Murphy serves on the editorial board of several scientific journals, and has published over 280 peer-reviewed articles, mostly on basic, translational and clinical studies related to chemokines and other chemoattractants. He has received numerous patents and awards including the NIAID Mentor of the Year Award, the NIH Director’s Award (twice), the Pillars of Immunology Award from the Journal of Immunology and both the Dolph Adams Award and the Bonazinga Award from the Society of Leukocyte Biology, and has had two papers selected as Classics by Science magazine. In addition, he has been elected to the Association of American Physicians, the American Society for Clinical Investigation, the American Society of Microbiology, the American Society of Biochemistry and Molecular Biology, and the Henry Kunkel Society.
Talk title: Treatment and cure strategies for WHIM syndrome immunodeficiency
Prof. Manuel Perucho
Institute of Predictive and Personalized Medicine of Cancer (IMPPC), Spain
Manuel Perucho completed his Ph.D. at the University of Madrid, and continued as a postdoctoral researcher at the Max-Planck-Institut, Berlin, and Cold Spring Harbor Laboratory, New York. He held appointments at the State University of New York (SUNY) at Stony Brook as Assistant and Associate Professor (1982-1987), and Research Program Director at the California Institute for Biological Research (CIBR) in La Jolla (1988-1995). From 1995 to 2009 he was Professor and Program Director at the Burnham Institute for Medical Research in La Jolla, California, where he currently holds an appointment as Adjunct Professor at Sanford-Burnham-Prebys Medical Discovery Institute (SBP), La Jolla, California.
Prof. Perucho was Director of the Institute for Predictive and Personalized Medicine of Cancer (IMPPC) in Barcelona (2009-2016), and currently is Director of the Program of Predictive and Personalized Medicine of Cancer (PMPPC) of the Institute Germans Trias I Pujol (IGTP), Barcelona, Spain.
He was awarded the AACR Professorship in Basic Cancer Research in 2005. He serves in editorial boards of several international journals and has reviewed research grants of many agencies and hundreds of papers of over 50 journals. His NCI-NIH grants surpassed the 20 million dollars and his current Spanish Government grants over 7 million euros. He has published over 150 papers with a total number of citations of over 15,000 with a h-index of 52.
Prof. Perucho is a scientist with training in basic and translational science. He has a long-lasting interest in the molecular genetics of malignancy. Prof. Perucho’s work made seminal contributions in the isolation and characterization of the first human oncogenes in the early eighties. Subsequently, his work opened a new field of cancer research by discovering microsatellite instability (MSI) in the nineties. These research contributions were published in top journals (Cell, Nature, Science, PNAS, etc). Prof. Perucho continues these studies on the mechanisms underlying gastrointestinal cancer pathogenesis and the role of genetic and epigenetic alterations in cancer susceptibility, and tumor development and progression. The dissection of these genetic and epigenetic somatic alterations has clinical applications. For instance, MSI delineated a distinct pathway for CC that offered new avenues for the diagnosis of cancer predisposition in hereditary cases that are used in the clinical practice worldwide.
Talk title: The epigenetics of colon cancer & the GCAT|Genomes for Life: A Cohort of the Genomes of Catalonia
Prof. Søren Brunak
Technical University of Denmark
Søren Brunak is a professor and Programme Director at the Novo Nordisk Foundation Center for Protein Research. He is a leading pioneer in the biomedical sciences through invention and introduction of new computational strategies for analysis of biological data for use in molecular biology, medicine and biotechnology. Søren Brunak has amongst other things published close to 300 papers in international peer-reviewed scientific journals and co-authored four books.
Talk title: Coming soon